Financials

v3.25.3
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Sep. 30, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 11,403,766 $ 864,840
Prepaid expenses and other current assets 1,301,778 607,670
Total current assets 12,705,544 1,472,510
Total assets 12,705,544 1,472,510
Current liabilities:    
Accounts payable and accrued expenses 2,479,272 1,355,867
Short-term notes payable, net of debt issuance costs 394,836 328,528
Total liabilities 2,874,108 1,684,395
Stockholders’ equity (deficit):    
Preferred stock, no par value; 50,000,000 shares authorized; 432,122 Series H and 7,488,692 Series F outstanding at September 30, 2025, and 0 Series H and 7,488,692 Series F outstanding at December 31, 2024.
Common stock, $0.001 par value; 350,000,000 shares authorized; 4,127,173 and 419,003 shares issued and outstanding at September 30, 2025, and December 31, 2024, respectively 4,127 419
Additional paid-in capital 234,169,098 216,573,868
Accumulated deficit (224,341,789) (216,786,172)
Total stockholders’ equity (deficit) 9,831,436 (211,885)
Total liabilities and stockholders’ equity (deficit) $ 12,705,544 $ 1,472,510

Source

v3.25.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Operating expenses:        
Research and development $ 930,894 $ 879,041 $ 1,722,115 $ 2,449,234
General and administrative 2,192,879 1,558,239 5,142,087 4,754,149
Total operating expenses 3,123,773 2,437,280 6,864,202 7,203,383
Loss from operations (3,123,773) (2,437,280) (6,864,202) (7,203,383)
Other income (expense):        
Interest income 68,142 9,466 95,138 35,106
Interest expense (7,039) (9,971) (778,476) (18,859)
Foreign currency exchange net (3,919) (25,085) (8,077) (31,659)
Total other income (expense), net 57,184 (25,590) (691,415) (15,412)
Net loss $ (3,066,589) $ (2,462,870) $ (7,555,617) $ (7,218,795)
Basic net loss per share $ (1.96) $ (11.32) $ (5.16) $ (101.37)
Diluted net loss per share $ (1.96) $ (11.32) $ (5.16) $ (101.37)
Weight-average shares outstanding, basic 1,560,909 217,602 1,464,689 71,211
Weight-average shares outstanding, diluted 1,560,909 217,602 1,464,689 71,211

Source

v3.25.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Cash flows from operating activities:    
Net loss $ (7,555,617) $ (7,218,795)
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization of debt discount and closing costs 771,437
Stock-based compensation expense 30,525 458,366
Stock-based compensation recapture expense (86,617)
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets (694,108) 49,951
Operating lease right of use assets 9,811
Accounts payable and accrued expenses 1,123,405 131,449
Change in operating lease liabilities (9,811)
Net cash used in operating activities (6,410,975) (6,579,029)
Cash flows from financing activities:    
Borrowings on short-term notes payable 2,623,399
Payments on short-term notes payable (3,328,528) (430,283)
Net proceeds from issuance of preferred stock and warrants 15,019,700
Net proceeds from issuance of common stock 2,635,330 6,669,860
Net cash provided by financing activities 16,949,901 6,239,577
Net decrease in cash and cash equivalents 10,538,926 (339,452)
Cash and cash equivalents at beginning of period 864,840 3,483,501
Cash and cash equivalents at end of period 11,403,766 3,144,049
Supplemental disclosure of cash flow information:    
Interest paid $ 14,899 $ 18,859

Source